GlassScriptPhysician profile
George Alva
NPI 1639766140
$3,532.63
in general payments reported to CMS, 2019-2025
24 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $400 · 2023: $873 · 2024: $845 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,751 · Education: $200 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,750.68 |
| Education | $199.98 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $517.49 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $491.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Harmony Biosciences LLC | $433.96 | 2024-2025 | |
| Abbott Laboratories | $357.09 | 2023-2025 | Freestyle Libre, Freestyle Libre 3, Freestyle Insulinx |
| Pfizer INC. | $272.66 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.38 | 2022-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $145.38 | 2022 | |
| Novo Nordisk INC | $138.13 | 2023-2025 | Saxenda, Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.99 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $50.60 | 2025 | Sunosi |
| Antares Pharma, INC. | $45.08 | 2022 | |
| Medtronic, INC. | $42.49 | 2024-2025 | Minimed 780g |
| Jazz Pharmaceuticals INC. | $38.21 | 2022 | |
| Edwards Lifesciences Corporation | $36.81 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $30.74 | 2021 | |
| Glaxosmithkline, LLC. | $30.29 | 2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.70 | 2022 | |
| Corium, LLC | $23.68 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $22.64 | 2023 | Ajovy |
| Astellas Pharma US INC | $21.80 | 2024 | Veozah |
| Tris Pharma INC | $21.22 | 2024 | Dyanavel Xr |
| Halozyme INC | $19.07 | 2023 | |
| Genentech USA, INC. | $7.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Alva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.